Abstract:Background The emergence of drug-eluting stents (DES) has dramatically reduced the incidence of in-stent restenosis. This study was conducted to evaluate the safety and efficacy of sirolimus-eluting cobalt-chrome stents (Firebird 2) for treating patients with coronary artery disease.Methods Sixty-seven patients with de novo or non-stented restenostic coronary lesions were chosen to receive the Firebird 2 stent as the final treatment (Firebird 2 group). Another 49 consecutive patients were implanted with bare cobalt alloyed stents (Driver, Medtronic) within the previous six months and served as historical controls (control group). Baseline clinical characteristics, angiographic features, procedural results, 30-day, 6-month and 12-month clinical follow-up regarding the occurrence of major adverse cardiac events (MACE), as well as the primary endpoint of late lumen loss at 6-month angiographic follow-up were compared between the two groups.Results The demographic characteristics were similar between the two groups despite more patients in the Firebird 2 group who underwent previous percutaneous coronary intervention (22.4% vs 8.2%, P=0.0418) and who had diabetes mellitus (29.9% vs 12.2%, P=0.0253). In the Firebird 2 group, the mean diameter of the reference vessel was smaller ((2.79 +/- 0.46) mm vs (2.98 +/- 0.49) mm, P=0.0175) and more stents were implanted for each lesion (1.28 +/- 0.52 vs 1.10 +/- 0.30, P=0.0060). Other angiographic, procedural results and the device success rate were similar between the two groups. The MACE rate at 30-day and 3-month was the same, but significantly fewer MACE occurred in the Firebird 2 group at 6- and 12-month follow-up (1.5% vs 12.2% at 6 month, P=0.0168; 1.5% vs 26.5% at 12 month, P < 0.0001). The primary endpoint of late lumen loss at 6-month angiographic follow-up was significantly reduced in the Firebird 2 group (in-stent: (0.05 +/- 0.09) mm vs (0.98 +/- 0.61) mm; in-segment: (0.05 +/- 0.18) mm vs (0.72 +/- 0.59) mm; P < 0.0001) than the control group. One patient in the Firebird 2 group had in-segment restenosis (1.3%) while the rate in the control group (38.1 %) was significantly higher, P < 0.0001. Intravascular ultrasound examination was performed in 70.1 % of patients in the Firebird 2 group and revealed that the percentage of volumetric obstruction was (1.26 +/- 1.05) %. No stent thrombosis was observed in either group at 12-month follow-up.Conclusion The Firebird 2 sirolimus-eluting cobalt alloyed stent is safe and feasible in treating patients with coronary artery disease.

Effect comparison of domestic rapamycin eluting stent versus imported rapamycin eluting stent in patients with coronary atherosclerotic heart disease

Study of long-term safety and efficacy of domestic Firebird rapamycin-eluting stent

Clinical Contrast Investigation of Firebird and Cypher Rapamycin Eluting Stent

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Safety and Efficacy of the Cypher Select Sirolimus-Eluting Stent in the "real World" - Clinical and Angiographic Results from the China Cypher Select Registry

Comparison Of Rotational Atherectomy And Modified Balloons Prior To Drug-Eluting Stent Implantation For The Treatment Of Heavily Calcified Coronary Lesions

[Comparison of the Effects of Rapamycin-Eluting Stent Implantation and Coronary Artery Bypass Grafting in Treatment of Patients with Multi-Vessel Coronary Disease].

Long-term Outcomes of Patients with Coronary Heart Disease Treated with Domestic Sirolimus-Eluting Partner Coronary Stent

[Comparison of Rapamycin and Paclitaxel Eluting Stent in Patients with Multi-Vessel Coronary Disease].

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

A study of treatment with different drug eluting stents in coronary heart disease

AS-023: Efficacy and Safety of a Novel Non-Symmetrical, Biodegradable Polymer-Coated Sirolimus-Eluting Stent in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

A Meta-analysis on curative effect of sirolimus-eluting stent and paclitaxel-eluting stent in treatment coronary heart disease

The Impact of Everolimus Versus Other Rapamycin Derivative-Eluting Stents on Clinical Outcomes in Patients with Coronary Artery Disease: A Meta-Analysis of 16 Randomized Trials

resuIts of a biodegradabIe poIymer and rapamycin ■ coating stent for coronary artery disease

Firebird Sirolimus Eluting Stent Versus Bare Mental Stent in Patients with ST-segment Elevation Myocardial Infarction

TCT-837 Everolimus-eluting Versus Other Rapamycin Derivatives-Eluting Stents in Patients with Coronary Artery Disease: a Meta-Analysis of 16 Randomized Trials

Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the TARGET II Trial.

Short and Intermediate Term Clinical Outcome of Sirolimus-Eluting Stent Implantation in Patients with ST-segment Elevation Myocardial Infarction

Sirolimus-eluting Cobalt Alloyed Stents in Treating Patients with Coronary Artery Disease: Six-Month Angiographic and One-Year Clinical Follow-Up Result A Prospective, Historically Controlled, Multi-Center Clinical Study

Efficacy and Safety of Firebird Sirolimus-Eluting Stent in Treatment of Complex Coronary Lesions in Chinese Patients: One-Year Clinical and Eight-Month Angiographic Outcomes from the FIREMAN Registry.